Tübingen, 72074
Germany
University of Tübingen
nomogram, melanoma, survival, checkpoint inhibitors, anti-PD-1, first line, stage IV
early stage melanoma, CP-GEP, biomarkers, adjuvant therapy, risk stratification
melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis
Melanoma, sex, Targeted therapy, immune checkpoint inhibition therapy, Survival